P2.06-07 PD-L1 Expression Guidance on Sintilimab Versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

S.-Y.M. Liu,J.-Y. Deng,H.-H. Yan,M.-Y. Yang,C.-R. Xu,M.-Y. Zheng,B. Gan, X.-C. Zhang,H.-Y. Tu,J.-J. Yang, H.-J. Chen,B.-C. Wang, Y. Li, Q. Zhou,Y.-L. Wu

Journal of thoracic oncology（2023）

引用 0|浏览8

暂无评分

摘要

Increasing PD-1 inhibitors has been approved as 1st line standard treatment in advanced non-small cell lung cancer (NSCLC). CTONG1901 was to compare efficacy and safety of sintilimab and pembrolizumab, in monotherapy or in combined therapy with chemo in untreated advanced NSCLC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要